BioSpace News Archive

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.

Tivic Health® Systems, Inc. announced that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation.

Aegle Therapeutics Corp. today announced the first patient has been dosed in the Phase 1/2a clinical trial of AGLE-102™ for the treatment of severe second-degree burns.

It is estimated that approximately 165,000 people per year are affected by a traumatic brain injury in Canada.

Chimerix (NASDAQ:CMRX) today announced the publication of data in support of the Company’s first-in-class small molecule imipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research.

In response to the opioid crisis, researchers at Hospital for Special Surgery (HSS) are looking for alternate ways to reduce pain after orthopedic procedures.

Biocytogen Pharmaceuticals, a biotechnology company focused on the generation and validation of novel antibody-based therapeutics and specialized animal models for partners worldwide, announces the grand opening of a new 37,000 sqft. facility in Waltham, MA for its US-based subsidiary, Biocytogen Boston Corporation.

VintaBio named Jennifer Kingsley as its first Chief Commercial Officer to develop and implement the company’s commercial strategy.

Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK ® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis.